Company Product Description Indication Status
Arrowhead Pharmaceuticals Inc., of Pasadena, Calif. ARO-ENaC RNAi therapy Cystic fibrosis Filed an application for clearance to begin a phase I/IIa dose-escalation study to evaluate safety, tolerability and pharmacokinetic effects in healthy volunteers and to evaluate safety, tolerability and efficacy in patients with CF
Astellas Pharma Inc., of Tokyo Xospata (gilteritinib) FLT3 inhibitor Relapsed/refractory acute myelogenous leukemia NDA accepted for review by China's NMPA
Seneca Biopharma Inc., of Germantown, Md. NSI-566 Human neural stem cell therapy Amyotrophic lateral sclerosis Feedback from type C meeting with FDA on March 10, 2020, indicated existing phase I and II trial results support moving into phase III study; protocol design underway using agency guidance

Notes

For more information about individual companies and/or products, see Cortellis.

No Comments